Case Report

An unusual case of lead migration in occipital nerve stimulation: A case report and literature review

Rafael Caiado Vencio1, Paulo Eduardo Albuquerque Zito Raffa2, André Costa Corral Ponce3, Bruno Pricoli Malamud3, César Cozar Pacheco4, Paulo Roberto Franceschini4, Roger Thomaz Rotta Medeiros4, Paulo Henrique Pires de Aguiar4,5,6,7

1Department of Medicine, Graduation Medicine, Pontifical Catholic University of Goiás, Goiânia, Goiás, 2Department of Medicine, Graduation Medicine, Catanduva Medical School (FAMECA-UNIFIPA), Catanduva, São Paulo, 3Department of Medicine, Graduation Medicine, Faculty of Medicine of ABC, Santo André, São Paulo, 4Department of Neurosurgery, Santa Paula Hospital, São Paulo, 5Department of Neurology and Neurosurgery, University of Caxias do Sul, Caxias do Sul, Rio Grande do Sul, 6Department of Neurology, Pontifical Catholic University of São Paulo, São Paulo, Brazil, 7Department of Research and Innovation, Laboratory of Cellular and Molecular Biology, Faculty of Medicine of ABC, Santo André, São Paulo, Brazil.

E-mail: *Rafael Caiado Vencio - rcvencio@gmail.com; Paulo Eduardo Albuquerque Zito Raffa - pauloeduardoazr@gmail.com; André Costa Corral Ponce - andre.ponce@aluno.fmabc.net; Bruno Pricoli Malamud - bruno.malamud@gmail.com; César Cozar Pacheco - cesarpacheco.md@gmail.com; Paulo Roberto Franceschini - prfrance@yahoo.com.br; Roger Thomaz Rotta Medeiros - roger.rota@hotmail.com; Paulo Henrique Pires de Aguiar - phpaneurocir@gmail.com

*Corresponding author:
Rafael Caiado Vencio,
Graduation Medicine, Pontifical Catholic University of Goiás,
Goiânia, Goiás, Brazil.
rcvencio@gmail.com

Received: 13 February 2021
Accepted: 03 April 2021
Published: 26 April 2021

ABSTRACT

Background: Lead migration is a complication associated with occipital nerve stimulation (ONS). We present a rare case in which fibrosis in the stress relief loop caused lead migration in the treatment of occipital neuralgia.

Case Description: A 30-year-old woman with a 5-year history of refractory occipital neuralgia, who had been under ONS therapy for 2 months, presented with a sudden onset of typical occipital neuralgia pain associated with cervical muscles spasms and myoclonus. A skull radiography showed lead migration. The patient underwent surgery for lead repositioning. During surgery, we identified extensive fibrosis throughout the stress relief loop that produced several constriction points. The fibrosis in the stress relief loop increased tension on the lead during head-and-neck movement, causing progressive migration of the lead.

Conclusion: Although lead migration is a common complication of ONS, its association with fibrosis in the stress relief loop has not, to the best of our knowledge, been reported before. Lead migration can directly affect treatment outcome and it is, therefore, important to fully understand the possible mechanisms that can cause it and how to promptly manage them.

Keywords: Lead migration, Neuromodulation, Occipital nerve stimulation, Occipital neuralgia

INTRODUCTION

Occipital neuralgia is described as a paroxysmal shooting or stabbing unilateral pain in the greater, lesser, or third occipital nerve dermatome. Initial treatment includes occipital nerve block and pharmacological therapy. In the management of refractory occipital neuralgia, radiofrequency rhizotomy and occipital nerve stimulation (ONS) are therapeutic options, being ONS a more invasive procedure.[6,13]

ONS can be used in the treatment of neuropathic pain when conservative or less invasive therapies have failed. It has been used in the treatment of occipital neuralgia, persistent chronic migraine,
cluster headache, cervicogenic headache, and other painful disorders.[12,16,35] Lead migration, infection, lead fracture, skin erosion, and lead disconnection are complication associated with ONS.[9]

In this article, we report a case of a patient diagnosed with refractory occipital neuralgia that undergoes surgery for ONS and develops lead migration 2 months after surgery. An ONS system includes a lead, an internal pulse generator (IPG), and the lead extension. The lead extension connects the lead, in the occipital region, to the IPG, in the infraclavicular region. Since this is a pathway with high mobility, we produce a stress relief loop with the lead extension so that the lead does not migrate due to higher tension during flexion or extension of the head.

During surgery for lead repositioning, we observed that fibrosis throughout the stress relief loop was the cause for migration. The association of fibrosis in the stress relief loop and lead migration is a rare complication of ONS and has not, to the best of our knowledge, been reported before. We also conduct a literature review of all reported cases of lead migration in ONS in the past 10 years and discuss possible mechanisms that might cause lead migration. Lead migration directly affects treatment outcome and pain management and, hence, it is essential to understand the mechanisms that cause it, how to properly and promptly manage it, and how to prevent its recurrence.

CASE REPORT

A 30-year-old woman with a 5-year history of refractory occipital neuralgia, who had been under ONS therapy for 2 months, presented with a sudden onset of severe unilateral pain, originating in the right upper nuchal region and spreading to the occipital and parietal regions. The pain was described as stabbing, sharp, lancinating, and occurred in paroxysms. The patient also described spasms and myoclonus that occurred in the right trapezius, scalene, and supraspinatus muscles, a new symptomatic component that had not accompanied her typical occipital neuralgia pain before.

The patient had a history of microvascular decompression surgery 6 years before as a treatment for trigeminal neuralgia, with full remission of symptoms. She developed cerebral venous sinus thrombosis and mastoiditis as immediate postoperative complications, but they were appropriately and successfully managed.

Due to the failure of medical therapy for occipital neuralgia (pregabalin and duloxetine), the patient had been submitted to three percutaneous radiofrequency rhizotomies (1, 3, and 4 years ago) which provided immediate symptomatic relief and yielded significant pain control, but for a limited time. She had also received two occipital nerve blocks through local anesthesia, but with poor effect in long-term pain management.

The pain had become progressively more severe, more frequent and associated with nausea. As a result of the unresponsiveness to less invasive procedures, the patient underwent ONS 2 months ago.

ONS was employed through surgery. The patient was placed in prone position under anesthesia. A right paramedian incision was performed in the level of C1 vertebra and a pathway was carefully dissected over the muscle fascia, toward the mastoid region. Once the correct position was asserted through fluoroscopy, a lead containing 16 electrode contacts was inserted and anchored over the muscle fascia. The IPG was placed in the infraclavicular region, in a subcutaneous pocket, and connected to the lead extension, which was inserted through subcutaneous tunneling. A stress relief loop was produced with the lead cable extension in the subcutaneous pocket, alongside the IPG, forming a circular coil to minimize tension on the lead [Figure 1]. The technique provided adequate pain management after optimization of the IPG settings.

Two months after ONS were implemented, the patient suddenly started with the symptoms and manifestations described. When the ONS system was turned off, the spasms and myoclonus ceased. A skull radiography showed lead migration [Figure 2].

The patient underwent surgery for lead repositioning. During surgery, extensive fibrosis was identified throughout the lead extension loop, which was deemed as cause for the lead migration. The fibrosis produced numerous points of...
constriction along the stress relief loop, which provided tension over the lead during head-and-neck movement and caused its migration.

We conducted thorough dissection of the fibrotic tissue, releasing the stress relief loop, and removing the IPG from the infraclavicular subcutaneous pocket [Figure 3]. A low cervical incision was made over the dislocated lead position guided by fluoroscopy and new tunneling was performed due to important fibrosis in the subcutaneous that restrained the lead from being removed. The lead and cables were then removed through the infraclavicular incision. The lead was repositioned through the former occipital incision and the system was reinserted as described previously [Figure 4].

After lead repositioning, the patient did not experience any muscle spasms or myoclonus. The pain intensity significantly decreased and the IPG settings are still being managed to optimize pain control.

**DISCUSSION**

In this case report, extensive fibrosis constricted the stress relief loop. Therefore, the loop was not able to relieve tension during movement of the head and neck, which resulted in lead tension, traction, and migration. The most common complications associated with ONS are lead migration, skin erosion, infection, lead fracture, and lead disconnection.

It is hard to properly assess the incidence of lead migration in ONS since the studies that report it are heterogeneous, describe few cases, and present extremely variable results [Table 1]. In our review, we identified five randomized clinical trials which reported lead migration.

These trials have reported a migration incidence that ranges from 12.9% to 50.9%. If we exclude from our review individual case reports, the migration incidence observed ranges from 1.8% to 57.1% [Table 1]. Studies with longer follow-up have observed a higher incidence of lead migration. Nonetheless, in this case report, lead migration was detected only 2 months after surgery.

Lead migration is a complication often reported in ONS [Table 1], but most authors have not identified or informed a clear cause for migration. When a presumptive cause was identified, it included a defect in the lead anchor, iatrogenic lead migration during IPG implantation, and repeated extension traction due to high mobility in the implanted area. The association of fibrosis and lead migration has not, to the best of our knowledge, been reported before in literature.

Other factors could also be associated a higher incidence of lead migration. It is reported that cylindrical leads could be more associated with migration than paddle-shaped leads since the shape and the dimensions of a cylindrical lead make it harder to anchor it to the fascia and increases the rate of skin erosion and lead migration.

The IPG location can also impact migration. A study described that infracervical or low abdomen sites are associated with less pathway length change during flexion and extension than periscapular or gluteal sites and, thus, generate less tension and could be less associated with lead migration.

Nevertheless, even though we employed techniques to reduce strain on the lead such as forming circular coils with the lead extension, implanting the IPG in an infracervical site, not using a cylindrical lead, and anchoring the lead according to manufacturer's specifications, none of these measures could prevent lead migration in the face of fibrosis around the ONS system.

The stress relief loop was positioned in the distal end of the lead extension, in an infracervical pocket, alongside the IPG. The positioning of the loop close to the IPG could be
associated with migration, although this relation has not been proposed by other studies before. Some authors suggest that the creation of an additional stress relief loop, producing one in the proximal end and another in the distal end of the extension, could reduce migration.\[10,33\]

Another limitation that increases the incidence of migration is that leads produced specifically for ONS are not widely available. Leads designed for spinal cord stimulation are often the only alternative, as were the case with this patient and an issue also reported by other authors.\[10\]

**Table 1:** Studies published in the past 10 years reporting lead migration in ONS.

| Study design                  | Diagnosis                    | Lead migration incidence (%) | Time until migration |
|-------------------------------|------------------------------|------------------------------|----------------------|
| Saper et al.\[31\]           | Chronic migraine             | 12/51 (23.5)                 | 3 months             |
| Magis et al.\[22\]           | Cluster headache             | 1/15 (6.6)                   | 7 days               |
| Wolter et al.\[41\]          | Cluster headache             | 2/7 (28.6)                   | 4.5 months           |
| Abejón et al.\[1\]           | Chronic migraine             | 4/31 (12.9)                  | N/A                  |
| Vadivelu et al.\[40\]        | Chiari malformation          | 3/15 (20.0)                  | N/A                  |
| Son et al.\[36\]             | Refractory hypnic headache   | 1/1 (100.0)                  | 1 year               |
| McGreevy et al.\[20\]        | Occipital neuralgia          | 1/1 (100.0)                  | 11 months            |
| Serra et al.\[32\]           | Chronic migraine             | 3/29 (10.3)                  | N/A                  |
| Mueller et al.\[23\]         | Chronic headache             | 1/27 (3.7)                   | 46 months            |
| Palmasi et al.\[27\]         | Chronic migraine             | 2/23 (8.7)                   | N/A                  |
| Silberstein et al.\[24\]     | Chronic migraine             | 20/157 (12.7)                | 12 weeks             |
| Lambru et al.\[17\]          | Secondary chronic SUNCT      | 1/9 (11.1)                   | N/A                  |
| Notaro et al.\[28\]          | Chronic migraine             | 5/17 (29.4)                  | 2 months             |
| Dodick et al.\[9\]           | Chronic migraine             | 29/57 (50.9)                 | N/A                  |
| Sharan et al.\[33\]          | Chronic migraine             | 27/157 (17.2)                | 96.7 days            |
| Reed et al.\[40\]            | Hemiplegic migraine          | 2/4 (50.0)                   | 6 months and 22 months |
| Plazier et al.\[29\]         | N/A                          | 3/92 (3.3)                   | 12 months            |
| Clark et al.\[7\]            | Chronic migraine             | 7/16 (43.7)                  | N/A                  |
| Magis et al.\[20\]           | Chronic migraine             | 1/15 (6.6)                   | N/A                  |
| Leone et al.\[18\]           | Cluster headache             | 6/35 (17.1)                  | 6.5 days             |
| Keifer et al.\[15\]          | Occipital neuralgia          | 1/29 (3.4)                   | N/A                  |
| Fontaine et al.\[11\]        | Cluster headache             | 2/58 (3.4)                   | N/A                  |
| Mekhail et al.\[22\]         | Chronic migraine             | 3/20 (15.0)                  | N/A                  |
| Miller et al.\[24\]          | Cluster headache             | 1/51 (2.0)                   | N/A                  |
| Jones et al.\[14\]           | Chronic daily headaches      | 12/21 (57.1)                 | N/A                  |
| Aibar-Durán et al.\[2\]      | Cluster headache             | 1/17 (5.9)                   | N/A                  |
| Ashkan et al.\[3\]           | Chronic migraine             | 2/112 (1.8)                  | N/A                  |
| Raoul et al.\[10\]           | Occipital headaches          | 6/60 (10.0)                  | N/A                  |
| Leplus et al.\[19\]          | Cluster headache             | 16/105 (15.2)                | N/A                  |

ONS: Occipital nerve stimulation, N/A: Not available, SUNCT: Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing

**Figure 4:** Repositioned lead after surgery.
Perhaps, an effective alternative to reduce lead migration associated with fibrosis would be a wireless ONS system that does not require an extension. Some studies report the use of such devices,[4,37,39] but they are not widely available and its usage would require more robust trials.

CONCLUSION

In this case report, the development of fibrosis throughout the ONS system caused constriction points in the stress relief loop that was responsible for lead migration. There is not, to the best of our knowledge, another published description of the association of fibrosis and lead migration.

Lead migration can hinder an effective treatment of occipital neuralgia and demands prompt intervention with lead repositioning. It is important to understand the mechanism responsible for lead migration to prevent it and to reposition the lead in an appropriate manner if it happens.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Abejón D, Calvo R, Arranz J, Pérez-Cajaraville J, del Saz J, Aguirre-Jaime A. Peripheral nerve stimulation in the treatment of various types of headache. Rev Esp Anestesiol Reanim 2011;58:589-94.
2. Aibar-Durán JA, Holzapfel MJ, Rodríguez RR, Nieto RB, Arnall CR, Teixido JM. Occipital nerve stimulation and deep brain stimulation for refractory cluster headache: A prospective analysis of efficacy over time. J Neurosurg 2020;2020:1-8.
3. Ashkan K, Sokratous G, Göbel H, Mehta V, Gendolla A, Dowson A, et al. Peripheral nerve stimulation registry for intractable migraine headache (RELIEF): A real-life perspective on the utility of occipital nerve stimulation for chronic migraine. Acta Neurochir (Wien) 2020;162:3201-11.
4. Burns B, Watkins L, Goadsby PJ. Treatment of hemicrania continua by occipital nerve stimulation with a bion device: Long-term follow-up of a crossover study. Lancet Neurol 2008;7:1001-12.
5. Chen YF, Bramley G, Unwin G, Hanu-Cernat D, Dretzke J, Moore D, et al. Occipital nerve stimulation for chronic migraines--a systematic review and meta-analysis. PLoS One 2015;10:e0116786.
6. Choi I, Jeon SR. Neuralgias of the head: Occipital neuralgia. J Korean Med Sci 2016;31:479-88.
7. Clark SW, Wu C, Boorman DW, Chalouhi N, Zanaty M, Oshinsky M, et al. Long-term pain reduction does not imply improved functional outcome in patients treated with combined supraorbital and occipital nerve stimulation for chronic migraine. Neuromodulation 2016;19:507-14.
8. Dodick DW, Silberstein SD, Reed KL, Deer TR, Slavin KV, Huh B, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2015;35:344-58.
9. Doran J, Ward M, Ward B, Paskhove B, Umanoff M, Mamalis A. Investigating complications associated with occipital nerve stimulation: A MAUDE study. Neuromodulation 2018;21:296-301.
10. Falowski S, Wang D, Sabesan A, Scharan A. Occipital nerve stimulation systems: Review of complications and surgical techniques. Neuromodulation 2010;13:121-5.
11. Fontaine D, Blond S, Lucas C, Regis J, Donnet A, Derrey S, et al. Occipital nerve stimulation improves the quality of life in medically-intractable chronic cluster headache: Results of an observational prospective study. Cephalalgia 2017;37:1173-9.
12. Göbel A, Göbel CH, Heinze A, Heinze-Kuhn K, Petersen I, Meinecke C, et al. Imaging sensory effects of occipital nerve stimulation: A new computer-based method in neuromodulation. Brain Stimul 2015;8:295-8.
13. Janjua MB, Reddy S, El Ahmadieh TY, Ban VS, Ozturk AK, Hwang SW, et al. Occipital neuralgia: A neurosurgical perspective. J Clin Neurosci 2020;71:263-70.
14. Jones JH, Brown A, Moyse D, Qi W, Roy L. Survival analysis of occipital nerve stimulator leads placed under fluoroscopic guidance with and without ultrasonography. Pain Physcian 2017;20:E1115-21.
15. Keifer OP Jr, Diaz A, Campbell M, Bezchlibnyk YB, Boulis NM. Occipital nerve stimulation for the treatment of refractory occipital neuralgia: A case series. World Neurosurg 2017;105:599-604.
16. Kovacs S, Peeters R, De Ridder D, Plazier M, Menovsky T, Sunaert S. Central effects of occipital nerve electrical stimulation studied by functional magnetic resonance imaging. Neuromodulation 2011;14:46-55; discussion 56-7.
17. Lambru G, Shanahan P, Watkins L, Matharu MS. Occipital nerve stimulation in the treatment of medically intractable SUNCT and SUNA. Pain Physician 2014;17:29-41.
18. Leone M, Proietti Cecchini A, Messina G, Franzini A. Long-term occipital nerve stimulation for drug-resistant chronic cluster headache. Cephalalgia 2017;37:756-63.
19. Leplu S, Fontaine D, Donnet A, Regis J, Lucas C, Buisset N, et al. Long-term efficacy of occipital nerve stimulation for medically intractable cluster headache. Neurosurgery 2021;88:375-83.
20. Magis D, Gerard P, Schoenen J. Invasive occipital nerve stimulation for refractory chronic cluster headache: What evolution at long-term? Strengths and weaknesses of the method. J Headache Pain 2016;17:8.
21. Magis D, Gerardy PY, Remacle JM, Schoenen J. Sustained effectiveness of occipital nerve stimulation in drug-resistant chronic cluster headache. Headache 2011;51:1191-201.
22. McGreevy K, Hameed H, Erdek MA. Updated perspectives on occipital nerve stimulator lead migration: Case report and literature review. Clin J Pain 2012;28:814-8.
23. Mekhail NA, Estemalik E, Azer G, Davis K, Tepper SJ. Safety and efficacy of occipital nerves stimulation for the treatment of chronic migraines: randomized, double-blind, controlled single-center experience. Pain Pract 2017;17:669-77.
24. Miller S, Watkins I, Matharu M. Treatment of intractable chronic cluster headache by occipital nerve stimulation: A cohort of 51 patients. Eur J Neurol 2017;24:381-90.
25. Mueller O, Diener HC, Dammann P, Rabe K, Hagel V, Sure U, et al. Occipital nerve stimulation for intractable chronic cluster headache or migraine: A critical analysis of direct treatment costs and complications. Cephalalgia 2013;33:1283-91.
26. Notaro P, Buratti E, Meroni A, Montagna MC, Rubino FG, Voltolini A. The effects of peripheral occipital nerve stimulation for the treatment of patients suffering from chronic migraine: A single center experience. Pain Physician 2014;17:E369-74.
27. Palmisani S, Al-Kaisy A, Arcioni R, Smith T, Negro A, Lambru G, et al. A six year retrospective review of occipital nerve stimulation practice—controversies and challenges of an emerging technique for treating refractory headache syndromes. J Headache Pain 2013;14:67.
28. Plazier M, Camp TV, Mevnosky T, Ost J, De Ridder D, Vanneste S. A simple technique for surgical placement of occipital nerve stimulators without anchoring the lead. J Neurol Surg A Cent Eur Neurosurg 2016;77:441-6.
29. Raoul S, Nguyen JM, Kuhn E, de Chauvigny E, Lejczak S, Nguyen JP, et al. Efficacy of Occipital Nerve Stimulation to Treat Refractory Occipital Headaches: A Single-Institution Study of 60 Patients. Neuromodulation 2020;23:789-95.
30. Reed KL, Will KR, Conidi F, Bulger R. Concordant occipital and supraorbital neurostimulation therapy for hemiplegic migraine: initial experience; a case series. Neuromodulation 2015;18:297-303; discussion 304.
31. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011;31:271-85.
32. Serra G, Marchioretto F. Occipital nerve stimulation for chronic migraine: A randomized trial. Pain Physician 2012;15:245-53.
33. Sharan A, Huh B, Narouze S, Trentman T, Mogilner A, Vaisman J, et al. Analysis of adverse events in the management of chronic migraine by peripheral nerve stimulation. Neuromodulation 2015;18:305-12; discussion 312.
34. Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2012;32:1165-79.
35. Slavin KV, Isagulyan ED, Gomez C, Yin D. Occipital nerve stimulation. Neurosurg Clin N Am 2019;30:211-7.
36. Son BC, Yang SH, Hong JT, Lee SW. Occipital nerve stimulation for medically refractory hypnic headache. Neuromodulation 2012;15:381-6.
37. Strand NH, Trentman TL, Vargas BR, Dodick DW. Occipital nerve stimulation with the Bion® microstimulator for the treatment of medically refractory chronic cluster headache. Pain Physician 2011;14:435-40.
38. Trentman TL, Mueller JT, Shah DM, Zimmerman RS, Noble BM. Occipital nerve stimulator lead pathway length changes with volunteer movement: An in vitro study. Pain Pract 2010;10:42-8.
39. Trentman TL, Rosenfeld DM, Vargas BR, Schwedt TJ, Zimmerman RS, Dodick DW. Greater occipital nerve stimulation via the Bion microstimulator: Implantation technique and stimulation parameters. Clinical trial: NCT00205894. Pain Physician 2009;12:621-8.
40. Vadivelu S, Bolognese P, Milhorat TH, Mogilner AY. Occipital nerve stimulation for refractory headache in the Chiari malformation population. Neurosurgery 2012;70:1430-6; discussion 1436-7.
41. Wolter T, Kiemen A, Kaube H. High cervical spinal cord stimulation for chronic cluster headache. Cephalalgia 2011;31:1170-80.

How to cite this article: Caiaudo-Vencio R, Raffa PE, Ponce AC, Malanud BP, Pacheco CC, Franceschini PR, et al. An unusual case of lead migration in occipital nerve stimulation: A case report and literature review. Surg Neurol Int 2021;12:189.